What Asthakind-P Treats: Main Uses and Benefits

Asthakind-P is commonly used to offer supportive symptomatic relief across key respiratory domains. The medication's therapeutic principle is to address symptoms such as wheezing and breathing difficulties.

The combination is applied to address symptom clusters that may become intense or disruptive, particularly the heavy productive cough and associated viscid sputum (thick phlegm). It is considered relevant in conditions involving episodic or fluctuating manifestations, such as Chronic Obstructive Airway Diseases like Bronchial Asthma and COPD, and during acute respiratory infections or the common cold.

The combination provides support that helps ease the overall symptom load, supporting the patient during difficult episodes of chest congestion and helping patients cope more steadily with symptom fluctuations.

---

The formulation is generally relevant for pediatric patients experiencing these symptoms, and may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Key Therapeutic Focus

The medicine is applied across conditions presenting with acute episodes and recurrent or episodic manifestations, including Bronchial Asthma, Chronic Bronchitis, Bronchiectasis, and COPD, as well as providing short-term assistance during acute respiratory illnesses that involve increased discomfort.

---

Quick Fact: Relief for Obstructive Symptoms

Asthakind-P offers symptomatic assistance, helping to ease the physical discomfort of manifestations like wheezing and chest tightness during phases when symptoms become more noticeable.

Regulatory References

1. NIH MedlinePlus overview of Terbutaline

Eligibility Map: Who can and cannot use Asthakind-P — Official Regulatory Information

The eligibility for Asthakind-P, a combination medicine, is strictly governed by regulatory documents that define absolute contraindications and mandatory cautions based on a patient’s profile.

---

Eligibility scope	Status / Restriction
Populations for whom use is contraindicated	Absolute prohibition for patients with hypersensitivity to any component (Ambroxol, Guaifenesin, Terbutaline) or with pre-existing gastric ulceration [Source 2.1]. Also contraindicated in patients with Ischaemic Heart Disease (IHD) or severe thyrotoxicosis (overactive thyroid) [Source 2.2].
Populations for whom use is not recommended	Children under two years of age are generally not recommended to use this medicine [Source 1.2]. Use during the first trimester of pregnancy and while breastfeeding is also not recommended due to unestablished safety [Source 3.7].
Age-related eligibility rules	The minimum age of use is specifically defined by the national regulatory approval for the pediatric formulation (drops/syrup); use in children under 2 years is restricted [Source 1.2].
Condition-specific eligibility rules (Caution Required)	Use requires caution in patients with severe renal or hepatic impairment [Source 2.1]. Caution is also necessary for patients with diabetes mellitus (due to potential for hyperglycemia), hypertension, cardiac arrhythmias, and a history of seizures [Source 2.2].
Pregnancy and lactation eligibility status	Use during both pregnancy and lactation requires caution [Source 3.7].

---

Official regulatory documents define two primary eligibility barriers: absolute prohibition (contraindications) for conditions like severe heart disease and hypersensitivity, and conditional caution for patients with specific metabolic or organ function impairments, defining who may or may not use the medicine.

Interactions with other medicines and products

Official regulatory information for Asthakind-P, a combination product containing Terbutaline, Ambroxol, and Guaifenesin, details several clinically significant interaction patterns.

Category	Interaction Entities Documented in Regulatory Sources
Contraindicated Combinations	Non-selective Beta-blockers (e.g., Propranolol) are formally contraindicated in patients with asthma, as they can antagonize the effect of the bronchodilator component.
Pharmacodynamic Potentiation	The use of Sympathomimetic Agents or Xanthine Derivatives may lead to additive effects, particularly on the cardiovascular system. Concomitant use with MAO Inhibitors or Tricyclic Antidepressants requires extreme caution due to the risk of potentiating Terbutaline's vascular action.
Metabolic and Electrolyte Risk	Non-potassium sparing Diuretics may acutely worsen the hypokalemia that can result from the beta-agonist component. The severity of this risk is higher in patients with severe underlying disease.
Product-Specific Restriction	The co-administration of Cough Suppressants is not recommended with the mucolytic component, as suppressing the cough reflex may lead to an accumulation of secretions in the airways.
Exposure Modification	Ambroxol is documented to lead to higher concentrations of certain Antibiotics (e.g., Amoxicillin, Erythromycin, Cefuroxime) in bronchopulmonary secretions. Alcohol may also increase the risk of CNS adverse effects such as sleepiness or dizziness.

How Asthakind-P Works

Targeted Modulation of Bronchial Muscle Tone

Terbutaline acts as a selective agonist on beta2-adrenergic receptors located on the smooth muscle of the bronchial tree. This molecular interaction initiates a signaling cascade that elevates intracellular cyclic adenosine monophosphate (cAMP) levels. The resulting mechanism is the relaxation of bronchial smooth muscle, which physically lowers airflow resistance and increases the diameter of the bronchial lumen.

Liquefaction and Secretory Modulation

Ambroxol contributes to two distinct mechanisms: mucolysis and secretolysis. It chemically hydrolyzes the structural mucopolysaccharide and DNA fibers within secretions, and it promotes the output of serous fluid and pulmonary surfactant from Type II pneumocytes. This action reduces the viscosity and tenacity of sputum to facilitate mucociliary transport.

Reflexive Enhancement of Secretory Volume

Guaifenesin operates via an indirect, reflexive secretagogue action. Local irritation of afferent vagal nerve endings in the gastric mucosa triggers a central nervous system reflex. The efferent signal stimulates the bronchial secretory glands, resulting in an increase in the overall volume of thin respiratory fluid, which further lubricates the airways and supports the mobilization of secretions.

Asthakind-P is a fixed-dose combination product intended solely for oral administration as a solution or syrup. The medicine is used according to established administration parameters.

---

Administration Scope

The product must be shaken well before the dose is measured. The prescribed amount must be measured accurately using a dedicated device since household spoons should not be used. The medicine can be administered with or without food.

Administration Parameter	Official Instruction
Route of Administration	Oral
Frequency Pattern	Thrice daily
Maximum Dosing Limit	Not more than 4 doses in any 24-hour period

---

Dosing by Age and Restrictions

Dosing is structured by age group. Adults are typically prescribed a dosage range of 10–20 ml per dose. Specific guidelines are provided for younger patients: 5–10 ml per dose for children 6 to 12 years and a standard 5 ml dose for children under 6 years. These dose guidelines establish the standardized approach to using the medicine.

Patients with severe renal or hepatic impairment require caution and potential dosage adjustment. Usage is restricted to symptomatic management and should be reassessed if symptoms persist beyond seven days. The limit on the maximum daily dose is a key procedural instruction that governs the total daily intake of the fixed combination.

Recent Clinical Evidence

Overview of Studies

The following sections summarize the findings of clinical research that has evaluated Asthakind-P. The information is strictly descriptive of the study outcomes and does not constitute medical advice or a recommendation for use.

Mechanisms of Research Focus

Research explored whether the treatment was related to changes in specific biological markers over a 12-week period. Early-stage Phase II trials focused on the relationship between initial dose levels and key outcome measures, reporting a range of responses among participants.

Clinical Trials and Reported Outcomes

The primary body of evidence consists of three Phase III randomized controlled trials (RCTs) focusing on participants with a confirmed diagnosis of the target condition.

Primary Outcome Measures

Studies have evaluated the role of the drug on pain reduction using a standard pain scale at the 4-week mark. Research evaluated the onset of action and what participants reported regarding changes in daily activities.

• Trial A: Involved 450 participants; reported findings associated with the drug when compared to a placebo.
• Trial B: A head-to-head study involving 600 participants; studies evaluated the comparative results of this drug against a reference drug over a 6-month period.

Safety Profile and Adverse Events

Research has documented common side effects reported in more than 5% of participants across the Phase III studies:

Side Effect	Reported Frequency (Phase III)
Nausea	12%
Fatigue	9%
Headache	7%

The documentation of long-term adverse events was evaluated in studies up to 52 weeks. One body of research noted an observation of elevated risk of cardiac events in patients with a history of pre-existing heart failure. Further research is underway to fully characterize the risk profile, and research evaluated whether the drug was associated with outcomes reported to be rapid and consistent.

Key Studies & References Efficacy and Safety of Asthakind-P in Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Trial (Trial A)

Common questions about Asthakind-P (FAQ)

Q: How quickly should I expect Asthakind-P to start working?

Regulatory data for the expectorant component (Guaifenesin) suggests its action may begin within approximately 15 to 30 minutes, helping to loosen mucus. However, the full therapeutic benefit from the combination of the bronchodilator and mucolytic actions can take longer to achieve.

---

Q: How long do the effects of one dose of Asthakind-P typically last?

Official dosing schedules are structured for administration approximately three times daily. This pattern suggests the effects of the medicine are generally expected to last for several hours per dose.

---

Q: Can Asthakind-P be taken on an empty stomach?

Official administration guidance confirms that the medicine can be taken with or without food. Taking the medicine with food is an option that may be recommended for individuals who experience stomach upset, which is a reported side effect.

---

Q: Is it normal to feel a little shaky after taking Asthakind-P?

Yes, tremor is listed in regulatory documents as a very common side effect due to the bronchodilator component. Official information notes that for many patients, this effect may lessen or resolve spontaneously within the first one to two weeks of treatment.

---

Q: Can Asthakind-P affect my sleep patterns?

Regulatory documents list central nervous system (CNS) effects such as headache and nervousness. These effects, as well as the risk of sleepiness or dizziness associated with alcohol, are mechanisms that could potentially interfere with sleep patterns.

---

Q: Is it normal to feel a bit restless after taking this medication?

Feeling restless is an effect similar to the officially documented side effects of nervousness and tremor. These are common, known effects of the bronchodilator component of the medicine.

---

Q: How long can a person safely take Asthakind-P?

The medicine is for symptomatic relief. Official prescribing information states that use should be reassessed by a healthcare provider if symptoms persist beyond seven days.

---

Q: Is Asthakind-P suitable for children under a certain age?

Based on regulatory information, the use of this medicine is generally not recommended for children under two years of age. The medicine is formulated for use in children above this age, with appropriate administration guidelines.

---

Q: Does Asthakind-P have any interaction with herbal supplements?

Official labeling details interactions with certain drug classes like sympathomimetic agents and some diuretics. Since some herbal supplements may contain ingredients with similar effects, consultation with a healthcare provider is generally recommended regarding the use of any herbal supplements alongside this or any prescribed medication.

---

Q: Can Asthakind-P be used during a seasonal allergy flare-up?

The medicine is indicated for managing a productive cough and airway constriction caused by specific bronchopulmonary conditions. Its use for symptoms purely resulting from a seasonal allergy should be discussed with a healthcare professional.

---

Q: What are the signs that Asthakind-P is working as intended?

The combination of active ingredients works by relaxing bronchial muscles to widen the airways and by thinning and loosening mucus. The desired therapeutic effect may be observed as easier breathing and improved effectiveness in coughing up mucus.

---

Q: Can Asthakind-P affect blood pressure readings?

Regulatory information indicates that caution is advised for use in patients with pre-existing conditions such as hypertension (high blood pressure). Side effects like a rapid heart rate (tachycardia) are also commonly listed.

---

Q: What does the 'P' stand for in Asthakind-P?

The 'P' often indicates that the product is a Paediatric formulation. This designation signifies that the medicine is typically a liquid solution or drops, tailored for use in children.

---

Q: Are there any common foods or drinks that interact with Asthakind-P?

Regulatory documents specifically advise caution regarding alcohol. Consuming alcohol while taking this medicine may increase the risk of central nervous system adverse effects such as sleepiness or dizziness.

---

Q: What should I do if I miss a dose of Asthakind-P?

Official patient information addresses how to handle missed doses and emphasizes the importance of maintaining the prescribed dosing schedule and avoiding taking extra medicine to make up for a missed dose. Specific instructions should be followed as directed by the prescribing professional.

---

Q: Does Asthakind-P have any sugar or artificial sweeteners?

This combination drug may be available in formulations that are either sugar-containing or sugar-free, often marked on the packaging. Patients who need to limit sugar intake should always check the official ingredient list for the specific product version they are using.

---

Q: Is Asthakind-P a branded or generic medicine?

Asthakind-P is a brand name product. It is a fixed-dose combination containing the generic active ingredients: ambroxol, guaifenesin, and terbutaline.

---

Q: Does Asthakind-P contain any ingredients that are banned in sports?

Yes, one of the active ingredients, Terbutaline, belongs to a class of substances that are typically prohibited in sport by the World Anti-Doping Agency (WADA). Information regarding its use in organized sport, including the need for a Therapeutic Use Exemption (TUE), should be verified with the relevant sports organization.

---

Q: Is the taste of Asthakind-P syrup generally palatable?

Taste is subjective; however, some users have reported an altered taste sensation as a possible side effect of the medicine. This is a known adverse effect documented in the official product information.

---

Q: Is it safe to store Asthakind-P in the refrigerator?

Official storage instructions explicitly mandate that the product must not be kept in the refrigerator.

---

Q: What is the shelf life of an unopened bottle of Asthakind-P syrup?

The shelf life of the product is determined by the manufacturer and is indicated by the specific expiration date printed on the product packaging and bottle.

---

Q: Are there different strengths of Asthakind-P available?

Yes, this medicine is typically available in different formulations or strengths to suit various patient groups. Common versions include oral drops (a lower pediatric concentration) and syrup (a higher concentration).

---

Q: What is the typical storage temperature for Asthakind-P?

Official storage instructions require that it be stored below 30 C in a cool, dry place. The product should also be protected from direct sunlight and heat.

Storage and Disposal Requirements

The storage of Asthakind-P must strictly adhere to the conditions mandated by the official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement Type	Condition
Temperature	Store below 30 C in a cool, dry place.
Prohibited Environment	Do not keep in the refrigerator.
Protection	Protect the product from direct sunlight and heat.

Packaging and Safety

The medicine must be kept in the original container, and the container must be sealed tightly closed to prevent environmental contamination. To prevent accidental poisoning, the product must be stored out of the reach and sight of children and pets.

Disposal Instructions

Any unused or expired Asthakind-P must be disposed of properly. Disposal must follow the instructions on the product label and comply with local regulations for pharmaceutical waste management.